Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Chills
(2004): Martino R, Curr Med Res Opin 20(4), 485
(2002): Bowden R+, Clin Infect Dis 35(4), 359
(2000): Wingard JR+, Clin Infect Dis 31(5), 1155
Death
(2002): Johnson PC+, AnnInternMed137(2), 105
(2001): Collazos J+, Clin Infect Dis 33(7), E75
Fever
(2004): Martino R, Curr Med Res Opin 20(4), 485
Hepatotoxicity
(2002): Mohan UR+, Pediatr Pulmonol 33(6), 497
Injection-site pain
Injection-site reactions (sic)
(2004): Sundar S+, Clin Infect Dis 38(3), 377
(2003): Imhof A+, Clin Infect Dis 36(8), 943
(2002): Johnson PC+, AnnInternMed137(2), 105
(2000): Karthaus M+, Chemotherapy 46, 293
Injection-site thrombophlebitis
(1995): Goodwin SD+, Clin Infect Dis 20, 755
Myalgia/Myositis/Myopathy/Myotoxicity
Nephrotoxicity
(2006): Cesaro S+, Pediatr Transplant 10(2), 255
(2006): Chandrasekar P, Int J Antimicrob Agents 27 Suppl 1, 31
(2006): Jayasuriya NS+, Oral Dis 12(1), 67
(2006): Saliba F, Int J Antimicrob Agents 27 Suppl 1, 21
(2006): Ullmann AJ+, Clin Infect Dis 43(4), e29
(2006): Wasan KM+, Cancer Chemother Pharmacol 57(1), 120
(2005): Alexander BD+, Clin Infect Dis 40 Suppl 6, S414
(2005): Girmenia C+, Support Care Cancer 13(12), 987
(2005): Pai MP+, Antimicrob Agents Chemother 49(9), 3784
(2005): Uehara RP+, Sao Paulo Med J 123(5), 219 (30%)
(2005): Wegner B+, NephrolDialTransplant20(10), 2071
(2004): Holler B+, Pediatrics 113(6), e608
(2004): Subira M+, Eur J Haematol 72(5), 342
(2004): Yokote T+, Ann Hematol 83(1), 64
(2002): Deray G, J Antimicrob Chemother 49 Suppl 1, 37
(2002): Deray G+, Nephrologie 23(3), 119
(2002): Furrer K+, Swiss Med Wkly 132(23–24), 316
(2002): Girmenia C+, Am J Med 113(4), 351
(2002): Gubbins PO+, Pharmacotherapy 22(8), 961
(2002): Harbarth S+, Clin Infect Dis 35(12), e120 (12%)
(2002): Mohan UR+, Pediatr Pulmonol 33(6), 497
(2002): Slain D+, Clin Ther 24(10), 1636 (6%)
(2002): Ural AU+, Eur J Clin Pharmacol 57(11), 771
(2001): Cannon JP+, Pharmacotherapy 21(9), 1107 (14%)
(2001): Costa S+, Curr Opin Crit Care 7(6), 379
(2001): Eriksson U+, BMJ 322(7286), 579
(2001): Girmenia C+, Clin Infect Dis 33(6), 915
(2001): Karthaus M+, Wien Med Wochenschr 151(3–4), 80
(2001): Razzaque MS+, Nephron 89(3), 251
(2000): Cagnoni PJ+, J Clin Oncol 18(12), 2476
(2000): Fanos V+, JChemother12(6), 463
(2000): Sandler ES+, J Pediatr Hematol Oncol 22(3), 242 (12%)
(2000): Wingard JR+, Clin Infect Dis 31(5), 1155
(1999): Hoffman-Terry ML+, Am J Med 106(1), 44 (8%)
(1999): Mayer J+, Support Care Cancer 7(1), 51
(1999): Rowles DM+, Clin Infect Dis 29(6), 1564
(1999): Wingard JR+, Clin Infect Dis 29(6), 1402
(1998): Camp MJ+, Antimicrob Agents Chemother 42(12), 3103
(1998): Coukell AJ+, Drugs 55(4), 585
(1997): Miano-Mason TM, Cancer Pract 5(3), 176
Rhabdomyolysis
Thrombophlebitis (1–10%)
(1993): Dietze R+, Clin Infect Dis 17, 981
AMPICILLIN
Trade names: Amfipen; Ampicin; Binotal; D-Amp; Marcillin;
Penbritin; Penstabil; Principen; Pro-Ampi; Sinaplin; Taro-
Ampicillin Trihydrate; Totacillin (GSK); Totapen; Unasyn (Pfizer);
Vidopen
Indications: Susceptible strains of gram-negative and grampositive
bacterial infections
Category: Antibiotic, penicillin
Half-life: 1–1.5 hours
Clinically important, potentially hazardous interactions
with: allopurinol, anticoagulants, chloramphenicol, cyclosporine,
demeclocycline, doxycycline, erythromycin, methotrexate,
minocycline, oxytetracycline, sulfonamides, tetracycline
Note: Five to 10% of people taking ampicillin develop eruptions
between the 5th and 14th day following initiation of therapy. Also,
there is a 95% incidence of exanthematous eruptions in patients who
are treated for infectious mononucleosis with ampicillin. The
allergenicity of ampicillin appears to be enhanced by allopurinol or by
hyperuricemia. Ampicillin is clearly the more allergenic of the two
drugs when given alone
Reactions
AMPICILLIN 33
Skin
Acute generalized exanthematous pustulosis (AGEP)
(2003): Saissi EH+, Ann Dermatol Venereol 130(6-7), 612
(1996): Campbell GAM+, An bras derm 71(1), 519
(1995): Moreau A+, Int J Dermatol 34, 263 (passim)
(1994): Manders SM+, Cutis 54, 194
(1991): Roujeau J-C+, Arch Dermatol 127, 1333
Allergic reactions (sic) (1–10%)
(2003): Medrala W+, Pol Merkuriusz Lek 14(79), 39
(1993): Grover JK+, Indian J Physiol Pharmacol 37, 247 (2.9%)
Angioedema (